You just read:

Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting

News provided by

Mylan N.V. , Biocon Ltd.

03 Jun, 2016, 14:00 ET